Home LiteratureArticle Details
PMID: 11822882 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.

Experimental neurology ·Vol. 173 ·No. 2 ·2002-02-00 ·Pages 183-95

Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D

Abstract

Doubly transgenic mice expressing both a mutated amyloid precursor protein and a mutated presenilin-1 protein accumulate A(beta) deposits as they age. The early A(beta) deposits were found to be primarily composed of fibrillar A(beta) and resembled compact amyloid plaques. As the mice aged, nonfibrillar A(beta) deposits increased in number and spread to regions not typically associated with amyloid plaques in Alzheimer's disease. The fibrillar, amyloid-containing deposits remained restricted to cortical and hippocampal structures and did not increase substantially beyond the 12-month time point. Even at early time points, the fibrillar deposits were associated with dystrophic neurites and activated astrocytes expressing elevated levels of glial fibrillary acidic protein. Microglia similarly demonstrated increased staining for complement receptor-3 in the vicinity of A(beta) deposits at early time points. However, when MHC-II staining was used to assess the degree of microglial activation, full activation was not detected until mice were 12 months or older. Overall, the regional pattern of A(beta) staining resembles that found in Alzheimer disease; however, a progression from diffuse A(beta) to more compact amyloid deposits is not observed in the mouse model. It is noted that the activation of microglia at 12 months is coincident with the apparent stabilization of fibrillar A(beta) deposits, raising the possibility that activated microglia might clear fibrillar A(beta) deposits at a rate similar to their rate of formation, thereby establishing a relatively steady-state level of amyloid-containing deposits.

MeSH Terms
Aging/pathology Alzheimer Disease/genetics,pathology Amyloid beta-Protein Precursor/genetics Animals Astrocytes/metabolism,pathology Brain/metabolism,pathology Brain Stem/metabolism,pathology Cell Count Disease Models, Animal Disease Progression Glial Fibrillary Acidic Protein/biosynthesis Histocompatibility Antigens Class II/biosynthesis Immunohistochemistry Membrane Proteins/genetics Mice Mice, Transgenic Microglia/metabolism,pathology Neurites/pathology Neurofibrillary Tangles/pathology Neurons/pathology Presenilin-1 Receptors, Complement/biosynthesis
Chemicals
Amyloid beta-Protein Precursor Glial Fibrillary Acidic Protein Histocompatibility Antigens Class II Membrane Proteins Presenilin-1 Receptors, Complement
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Gordon Marcia N
Alzheimer Research Laboratory, Department of Pharmacology, University of South Florida, Tampa, Florida 33612-4799, USA.
Holcomb Leigh A
Jantzen Paul T
DiCarlo Giovanni
Wilcock Donna
Boyett Kristal W
Connor Karen
Melachrino Jason
O'Callaghan James P
Morgan Dave
Article Info
Journal
Experimental neurology
Abbr.
Exp Neurol
ISSN
0014-4886
Published
2002-02-00
Pages
183-95
Language
English
Region
United States
NLM ID
0370712
Subset
IM
Grants
NIA NIH HHS · AG 15490 · United States
NIA NIH HHS · AG 18478 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com